Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1626GMS

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	DEC 01	ChemPort single article sales feature unavailable
NEWS 3	JAN 06	The retention policy for unread STNmail messages will change in 2009 for STN-Columbus and STN-Tokyo
NEWS 4	JAN 07	WPIDS, WPINDEX, and WPIX enhanced Japanese Patent Classification Data
NEWS 5	FEB 02	Simultaneous left and right truncation (SLART) added for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS 6	FEB 02	GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS 7	FEB 06	Patent sequence location (PSL) data added to USGENE
NEWS 8	FEB 10	COMPENDEX reloaded and enhanced
NEWS 9	FEB 11	WTEXTILES reloaded and enhanced
NEWS 10	FEB 19	New patent-examiner citations in 300,000 CA/CAplus patent records provide insights into related prior art
NEWS 11	FEB 19	Increase the precision of your patent queries -- use terms from the IPC Thesaurus, Version 2009.01
NEWS 12	FEB 23	Several formats for image display and print options discontinued in USPATFULL and USPAT2
NEWS 13	FEB 23	MEDLINE now offers more precise author group fields and 2009 MeSH terms
NEWS 14	FEB 23	TOXCENTER updates mirror those of MEDLINE - more precise author group fields and 2009 MeSH terms
NEWS 15	FEB 23	Three million new patent records blast AEROSPACE into STN patent clusters
NEWS 16	FEB 25	USGENE enhanced with patent family and legal status display data from INPADOCDB
NEWS 17	MAR 06	INPADOCDB and INPAFAMDB enhanced with new display formats
NEWS 18	MAR 11	EPFULL backfile enhanced with additional full-text applications and grants
NEWS 19	MAR 11	ESBIOBASE reloaded and enhanced
NEWS 20	MAR 20	CAS databases on STN enhanced with new super role for nanomaterial substances
NEWS 21	MAR 23	CA/CAplus enhanced with more than 250,000 patent equivalents from China
NEWS 22	MAR 30	IMSPATENTS reloaded and enhanced
NEWS 23	APR 03	CAS coverage of exemplified prophetic substances enhanced
NEWS 24	APR 07	STN is raising the limits on saved answers

```
 NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN customer
  agreement.  This agreement limits use to scientific research.  Use
  for software development or design, implementation of commercial
  gateways, or use of CAS and STN data in the building of commercial
  products is prohibited and may result in loss of user privileges
  and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:41:42 ON 21 APR 2009

=>
Uploading
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Do you want to switch to the Registry File?
Choice (Y/n):
Switching to the Registry File...
Some commands only work in certain files.  For example, the EXPAND
command can only be used to look at the index in a file which has an
index.  Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of
commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.22       0.22

FILE 'REGISTRY' ENTERED AT 10:41:57 ON 21 APR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   19 APR 2009  HIGHEST RN 1136834-47-3
DICTIONARY FILE UPDATES:  19 APR 2009  HIGHEST RN 1136834-47-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
```

predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10587846.str





chain nodes :
6 7 9 11 12 15
ring nodes :
1 2 3 4 5
chain bonds :
1-15 2-11 5-6 6-7 6-9 11-12
ring bonds :
1-2 1-5 2-3 3-4 4-5
exact/norm bonds :
1-2 1-5 1-15 2-3 3-4 4-5 6-7 6-9 11-12
exact bonds :
2-11 5-6
isolated ring systems :
containing 1 :

G1:Cb,Hy

G2:Cy,Hy,Ph

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 9:CLASS 11:CLASS
12:CLASS 15:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 Cb,Hy
G2 Cy,Hy,Ph

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 10:42:12 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 12855 TO ITERATE

15.6% PROCESSED 2000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 250306 TO 263894
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 10:42:19 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 260501 TO ITERATE

83.5% PROCESSED 217493 ITERATIONS 0 ANSWERS

100.0% PROCESSED 260501 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.23

L3 0 SEA SSS FUL L1

=>
Uploading C:\Program Files\Stnexp\Queries\10587846a.str





chain nodes :
7 10 11 14
ring nodes :
1 2 3 4 5 6 15 16
chain bonds :
1-14 2-10 5-6 6-7 10-11
ring bonds :
1-2 1-5 2-3 3-4 4-5 6-15 6-16 15-16
exact/norm bonds :
1-2 1-5 1-14 2-3 3-4 4-5 6-7 6-15 6-16 10-11 15-16
exact bonds :
2-10 5-6
isolated ring systems :
containing 1 :

G1:Cb,Hy

G2:Cy,Hy,Ph

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 10:CLASS 11:CLASS
14:CLASS 15:Atom 16:Atom

L4 STRUCTURE UPLOADED

=> d 14

L4 HAS NO ANSWERS
L4 STR



G1 Cb,Hy
G2 Cy,Hy,Ph

Structure attributes must be viewed using STN Express query preparation.

```
=> s l4
SAMPLE SEARCH INITIATED 10:45:00 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     5094 TO ITERATE

 39.3% PROCESSED     2000 ITERATIONS                                0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        97600 TO   106160
PROJECTED ANSWERS:               0 TO        0

L5            0 SEA SSS SAM L4

=> s l4 sss full
FULL SEARCH INITIATED 10:45:07 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   101216 TO ITERATE

100.0% PROCESSED   101216 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.08

L6            0 SEA SSS FUL L4

=>
Uploading C:\Program Files\Stnexp\Queries\10587846b.str
```





chain nodes :
9 10
ring nodes :
1 2 3 4 5 6 13 14 15 16 17 18 19 20
chain bonds :
2-9 5-6 6-16 9-10
ring bonds :
1-2 1-5 2-3 3-4 4-5 6-14 6-13 13-14 15-16 15-20 16-17 17-18 18-19
19-20
exact/norm bonds :
1-2 1-5 2-3 3-4 4-5 6-14 6-13 9-10 13-14
exact bonds :
2-9 5-6 6-16
normalized bonds :
15-16 15-20 16-17 17-18 18-19 19-20
isolated ring systems :
containing 1 :

G1:Cb,Hy

G2:Cy,Hy,Ph

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 9:CLASS 10:CLASS 13:Atom
14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom

L7 STRUCTURE UPLOADED

=> d l7
L7 HAS NO ANSWERS
L7 STR



G1 Cb,Hy
G2 Cy,Hy,Ph

Structure attributes must be viewed using STN Express query preparation.

=> s l7
SAMPLE SEARCH INITIATED 10:46:52 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 73 TO ITERATE

100.0% PROCESSED 73 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 948 TO 1972
PROJECTED ANSWERS: 0 TO 0

L8 0 SEA SSS SAM L7

=> s l7 sss full
FULL SEARCH INITIATED 10:46:59 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1574 TO ITERATE

100.0% PROCESSED 1574 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L9 0 SEA SSS FUL L7

=>
Uploading C:\Program Files\Stnexp\Queries\10587846c.str



ring nodes :
1 2 3 4 5 6 10 11 12 13 14 15 16 17 18 19 20 21 22 23
chain bonds :
2-22 5-6 6-13
ring bonds :
1-2 1-5 2-3 3-4 4-5 6-11 6-10 10-11 12-13 12-17 13-14 14-15 15-16
16-17 18-19 18-23 19-20 20-21 21-22 22-23
exact/norm bonds :
1-2 1-5 2-3 3-4 4-5 6-11 6-10 10-11
exact bonds :
2-22 5-6 6-13
normalized bonds :
12-13 12-17 13-14 14-15 15-16 16-17 18-19 18-23 19-20 20-21 21-22 22-23
isolated ring systems :
containing 1 : 18 :

G1:Cb,Hy

G2:Cy,Hy,Ph

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 10:Atom 11:Atom 12:Atom 13:Atom
14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom
23:Atom

L10 STRUCTURE UPLOADED

=> d l10
L10 HAS NO ANSWERS
L10 STR



G1 Cb,Hy
G2 Cy,Hy,Ph

Structure attributes must be viewed using STN Express query preparation.

```
=> s l10
SAMPLE SEARCH INITIATED 10:49:21 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       83 TO ITERATE

100.0% PROCESSED       83 ITERATIONS                                9 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          1114 TO     2206
PROJECTED ANSWERS:                9 TO      360

L11           9 SEA SSS SAM L10

=> s l10 sss full
FULL SEARCH INITIATED 10:49:38 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     1699 TO ITERATE

100.0% PROCESSED     1699 ITERATIONS                              209 ANSWERS
SEARCH TIME: 00.00.01

L12         209 SEA SSS FUL L10

=>
Uploading C:\Program Files\Stnexp\Queries\10587846d.str
```





chain nodes :
24 25 26 27 28
ring nodes :
1 2 3 4 5 6 10 11 12 13 14 15 16 17 18 19 20 21 22 23
chain bonds :
2-22 5-6 6-13 19-24 24-25 25-26 25-28 26-27
ring bonds :
1-2 1-5 2-3 3-4 4-5 6-11 6-10 10-11 12-13 12-17 13-14 14-15 15-16
16-17 18-19 18-23 19-20 20-21 21-22 22-23
exact/norm bonds :
1-2 1-5 2-3 3-4 4-5 6-11 6-10 10-11 19-24 24-25 25-28 26-27
exact bonds :
2-22 5-6 6-13 25-26
normalized bonds :
12-13 12-17 13-14 14-15 15-16 16-17 18-19 18-23 19-20 20-21 21-22 22-23
isolated ring systems :
containing 1 : 18 :

G1:Cb,Hy

G2:Cy,Hy,Ph

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 10:Atom 11:Atom 12:Atom 13:Atom
14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom
23:Atom 24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS

L13 STRUCTURE UPLOADED

=> d l13
L13 HAS NO ANSWERS

L13 STR



G1 Cb,Hy
G2 Cy,Hy,Ph

Structure attributes must be viewed using STN Express query preparation.

=> s l13
SAMPLE SEARCH INITIATED 10:52:07 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 13 TO ITERATE

100.0% PROCESSED 13 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 44 TO 476
PROJECTED ANSWERS: 0 TO 0

L14 0 SEA SSS SAM L13

=> s l13 sss full
FULL SEARCH INITIATED 10:52:15 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 309 TO ITERATE

100.0% PROCESSED 309 ITERATIONS 5 ANSWERS
SEARCH TIME: 00.00.01

L15 5 SEA SSS FUL L13

=>
Uploading C:\Program Files\Stnexp\Queries\10587846e.str





chain nodes :
24 26
ring nodes :
1 2 3 4 5 6 10 11 12 13 14 15 16 17 18 19 20 21 22 23
chain bonds :
1-26 2-22 5-6 6-13 19-24
ring bonds :
1-2 1-5 2-3 3-4 4-5 6-11 6-10 10-11 12-13 12-17 13-14 14-15 15-16
16-17 18-19 18-23 19-20 20-21 21-22 22-23
exact/norm bonds :
1-2 1-5 1-26 2-3 3-4 4-5 6-11 6-10 10-11 19-24
exact bonds :
2-22 5-6 6-13
normalized bonds :
12-13 12-17 13-14 14-15 15-16 16-17 18-19 18-23 19-20 20-21 21-22 22-23
isolated ring systems :
containing 1 : 18 :

G1:Cb,Hy

G2:Cy,Hy,Ph

G3:Cb,Hy

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 10:Atom 11:Atom 12:Atom 13:Atom
14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom
23:Atom 24:CLASS 26:CLASS

L16 STRUCTURE UPLOADED

```
=> d l16
L16 HAS NO ANSWERS
L16             STR
```



G1 Cb,Hy

G2 Cy,Hy,Ph

G3 Cb,Hy

Structure attributes must be viewed using STN Express query preparation.

```
=> s l16
SAMPLE SEARCH INITIATED 10:54:47 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       20 TO ITERATE

100.0% PROCESSED       20 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE   **COMPLETE**
                        BATCH    **COMPLETE**
PROJECTED ITERATIONS:          132 TO      668
PROJECTED ANSWERS:               0 TO        0

L17           0 SEA SSS SAM L16

=> s l16 sss full
FULL SEARCH INITIATED 10:54:54 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      413 TO ITERATE

100.0% PROCESSED      413 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

L18           0 SEA SSS FUL L16

=>
Uploading C:\Program Files\Stnexp\Queries\10587846f.str
```





```
chain nodes :
25
ring nodes :
1  2  3  4  5  6  10  11  12  13  14  15  16  17  18  19  20  21  22  23
chain bonds :
1-25  2-22  5-6  6-13
ring bonds :
1-2  1-5  2-3  3-4  4-5  6-11  6-10  10-11  12-13  12-17  13-14  14-15  15-16
16-17  18-19  18-23  19-20  20-21  21-22  22-23
exact/norm bonds :
1-2  1-5  1-25  2-3  3-4  4-5  6-11  6-10  10-11
exact bonds :
2-22  5-6  6-13
normalized bonds :
12-13  12-17  13-14  14-15  15-16  16-17  18-19  18-23  19-20  20-21  21-22  22-23
isolated ring systems :
containing 1 : 18 :


G1:Cb,Hy

G2:Cy,Hy,Ph

G3:Cb,Hy

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  10:Atom  11:Atom  12:Atom  13:Atom
14:Atom  15:Atom  16:Atom  17:Atom  18:Atom  19:Atom  20:Atom  21:Atom  22:Atom
23:Atom  25:CLASS



L19     STRUCTURE UPLOADED
```

=> d l19
L19 HAS NO ANSWERS
L19 STR



G1 Cb,Hy
G2 Cy,Hy,Ph
G3 Cb,Hy

Structure attributes must be viewed using STN Express query preparation.

=> s l19
SAMPLE SEARCH INITIATED 10:57:25 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 83 TO ITERATE

100.0% PROCESSED 83 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 1114 TO 2206
PROJECTED ANSWERS: 0 TO 0

L20 0 SEA SSS SAM L19

=> s l19 sss full
FULL SEARCH INITIATED 10:57:31 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1699 TO ITERATE

100.0% PROCESSED 1699 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L21 0 SEA SSS FUL L19

=> FIL HCAPLUS
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 1310.76 1310.98

FILE 'HCAPLUS' ENTERED AT 10:58:19 ON 21 APR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 21 Apr 2009 VOL 150 ISS 17
FILE LAST UPDATED: 20 Apr 2009 (20090420/ED)

HCAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> d his

(FILE 'HOME' ENTERED AT 10:41:42 ON 21 APR 2009)

FILE 'REGISTRY' ENTERED AT 10:41:57 ON 21 APR 2009
L1 STRUCTURE UPLOADED
L2 0 S L1
L3 0 S L1 SSS FULL
L4 STRUCTURE UPLOADED
L5 0 S L4
L6 0 S L4 SSS FULL
L7 STRUCTURE UPLOADED
L8 0 S L7
L9 0 S L7 SSS FULL
L10 STRUCTURE UPLOADED
L11 9 S L10
L12 209 S L10 SSS FULL
L13 STRUCTURE UPLOADED
L14 0 S L13
L15 5 S L13 SSS FULL
L16 STRUCTURE UPLOADED
L17 0 S L16
L18 0 S L16 SSS FULL
L19 STRUCTURE UPLOADED
L20 0 S L19
L21 0 S L19 SSS FULL

FILE 'HCAPLUS' ENTERED AT 10:58:19 ON 21 APR 2009

=> s l12
L22 5 L12

=> s l15
L23 1 L15

=> d l22 ibib abs hitstr tot

L22 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:1186333 HCAPLUS
DOCUMENT NUMBER: 149:548657
TITLE: Distinctive molecular inhibition mechanisms for selective inhibitors of human 11β-hydroxysteroid dehydrogenase type 1
AUTHOR(S): Tu, Hua; Powers, Jay P.; Liu, Jinsong; Ursu, Stefania; Sudom, Athena; Yan, Xuelei; Xu, Haoda; Meininger, David; DeGraffenreid, Michael; He, Xiao; Jaen, Juan C.; Sun, Daqing; Labelle, Marc; Yamamoto, Hiroshi; Shan, Bei; Walker, Nigel P. C.; Wang, Zhulun
CORPORATE SOURCE: Department of Metabolic Disorders, Amgen Inc., South San Francisco, CA, 94080, USA
SOURCE: Bioorganic & Medicinal Chemistry (2008), 16(19), 8922-8931
CODEN: BMECEP; ISSN: 0968-0896
PUBLISHER: Elsevier Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I



II

AB 11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) catalyzes the NADPH dependent interconversion of inactive cortisone to active cortisol. Excess 11β-HSD1 or cortisol leads to insulin resistance and metabolic syndrome in animal models and in humans. Inhibiting 11β-HSD1

activity signifies a promising therapeutic strategy in the treatment of Type 2 diabetes and related diseases. Herein, the authors report two highly potent and selective small mol. inhibitors of human 11β-HSD1. While compound (I), a sulfonamide, functions as a simple substrate competitive inhibitor, compound (II), a triazole, shows the kinetic profile of a mixed inhibitor. Co-crystal structures reveal that both compds. occupy the 11β-HSD1 catalytic site, but present distinct mol. interactions with the protein. Strikingly, compound (II) interacts much closer to the cofactor NADP+ and likely modifies its binding. Together, the structural and kinetic analyses demonstrate two distinctive mol. inhibition mechanisms, providing valuable information for future inhibitor design.

IT 1080025-70-2P
RL: BSU (Biological study, unclassified); DMA (Drug mechanism of action); PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and distinctive mol. inhibition mechanisms for selective inhibitors of human 11β-hydroxysteroid dehydrogenase type 1 and possible use for treatment of type 2 diabetes)

RN 1080025-70-2 HCAPLUS

CN 4H-1,2,4-Triazole, 3-[1-(4-fluorophenyl)cyclopropyl]-4-(1-methylethyl)-5-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:569372 HCAPLUS

DOCUMENT NUMBER: 143:97369

TITLE: Preparation of triazoles and related compounds as 11β-hydroxysteroid dehydrogenase 1 inhibitors

INVENTOR(S): Yamashita, Toshiro; Noda, Masakuni; Kawamoto, Tomohiro; Irie, Kazuyuki

PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 65 pp.
CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2005170939	A	20050630	JP 2004-337016	20041122

PRIORITY APPLN. INFO.: JP 2003-391476 A 20031120
OTHER SOURCE(S): MARPAT 143:97369
GI

I



II

AB Title compds. I [R1 = H, (un)substituted cyclic group; R2 = (un)substituted cyclic group; Ar = optionally furthermore substituted 5-, 6-membered heterocyclic ring; L1, L2 = bond, etc.] were prepared For example, benzylation of 4-ethyl-5-heptyl-2,4-dihydro-3H-1,2,4-triazol-3-thione, e.g., prepared from octanoyl hydrazide in 2 steps, with 2,6-dichlorobenzyl chloride afforded compound II. In 11βHSD1 (11β-hydroxysteroid dehydrogenase type 1) inhibition assays, the IC50 value of compound II was 39 nM. Of note, compds. I are useful for the treatment of diabetes. Formulations are given.

IT 856701-52-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of triazoles and related compds. as 11β-hydroxysteroid dehydrogenase 1 inhibitors)

RN 856701-52-5 HCAPLUS
CN 4H-1,2,4-Triazole, 3-phenyl-5-(1-phenylcyclopropyl)-4-(2-phenylethyl)- (CA INDEX NAME)



L22 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:423718 HCAPLUS
DOCUMENT NUMBER: 142:482046
TITLE: Preparation of triazole compounds as 11β-hydroxysteroid dehydrogenase 1 inhibitors
INVENTOR(S): Cardozo, Mario G.; Powers, Jay P.; Goto, Hiroyuki;

Harada, Kazuhito; Imamura, Katsuaki; Kakutani, Makoto; Matsuda, Isamu; Ohe, Yasuhiro; Yata, Shinji

PATENT ASSIGNEE(S): Amgen SF LLC, USA; Japan Tobacco, Inc.
SOURCE: PCT Int. Appl., 107 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005044192	A2	20050519	WO 2004-US35805	20041027
WO 2005044192	A3	20050909		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004286836	A1	20050519	AU 2004-286836	20041027
CA 2543602	A1	20050519	CA 2004-2543602	20041027
EP 1680114	A2	20060719	EP 2004-796647	20041027
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
JP 2007509959	T	20070419	JP 2006-538245	20041027
MX 2006004674	A	20061120	MX 2006-4674	20060426
US 20080249084	A1	20081009	US 2006-587846	20060905
PRIORITY APPLN. INFO.:			US 2003-515537P P	20031028
			WO 2004-US35805 W	20041027

OTHER SOURCE(S): CASREACT 142:482046; MARPAT 142:482046

GI



I

Q=

Q^1=



Q^2=



AB The present invention provides triazole compds. of the following formula (I)or prodrugs thereof or pharmaceutically acceptable salts thereof [R1 = (un)substituted alkyl or cycloalkyl; Y = each (un)substituted cycloalkyl or heterocycloalkyl; Ar1 = aryl, heteroaryl; R2, R3 = H, halo, haloalkyl, alkyl group, (CH2)nOH, -N(R9)(R10), cyano, NO2, alkoxy, cycloalkyl, alkenyl, COR11, each (un)substituted aryl or heteroaryl group [wherein R9, R10 = H, alkyl,alkylcarbonyl; R11 = OH, alkoxy, alkyl, (un)substituted NH2; n = 0-3]; Z = [CH(R14)]p, [CH(R14)]p-N(R16)[CH(R15)]q, each (un)substituted cycloalkylidene or heterocycloalkylidene [wherein p, q = 0-3; R14, R15 = group listed in R9 and R10]; Ar2 = aryl, heteroaryl, Q, Q1, Q2 [wherein X1 = (CH2)t; t = 0-2; V1 = :CH, :N; W1 = (un)substituted CH2, O, S, SO2, SO, CO, (un)substituted NH]; R4, R5 = H, halo, OH, NO2, cyano, alkyl, alkoxy, COR27, SO2R27, each (un)substituted CONH2 or NH2; R27 = OH, alkoxy, alkyl, NH2, alkylamino, dialkylamino]. These triazole compds. are 11β-hydroxysteroid dehydrogenase 1-(11β-HSD1 or HSD1) and useful as therapeutic drugs for the treatment of diabetes, obesity or metabolic syndrome. Thus, Me N-methyl-4-phenylpiperidine-1-imidethiocarboxylate hydroiodide (452 mg) and 1-phenylcyclopropane carbohydrazide (176 mg) were suspended in 1,4-dioxane (2 mL) and water (0.4 mL) and sodium acetate (98 mg) were added and the mixture was heated under reflux overnight to give, after workup and silica gel chromatog., 117 mg 1-[4-methyl-5-(1-phenylcyclopropyl)-4H-[1,2,4]triazol-3-yl]-4-phenylpiperidine hydrochloride (II). II showed IC50 of <10 nM against human HSD1.

IT 1044957-17-6 1044957-18-7 1044957-19-8
1044957-20-1 1044957-21-2 1044957-22-3
1044957-23-4 1044957-24-5 1044957-25-6
1044957-46-1 1044957-47-2 1044957-48-3
1044957-49-4 1044957-50-7 1044957-51-8
1044957-55-2 1044957-56-3 1044957-65-4
1044957-67-6 1044957-68-7 1044957-69-8
1044957-70-1 1044957-71-2 1044957-72-3
1044957-73-4 1044957-74-5 1044957-75-6
1044957-76-7 1044957-77-8 1044957-78-9
1044957-79-0 1044957-80-3
RL: PRPH (Prophetic)
(Preparation of triazole compounds as 11β-hydroxysteroid dehydrogenase 1 inhibitors)

RN 1044957-17-6 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED



RN 1044957-18-7 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED



RN 1044957-19-8 HCAPLUS
CN 4H-1,2,4-Triazole, 3-(3-fluorophenyl)-5-[1-(4-fluorophenyl)cyclopropyl]-4-(1-methylethyl)- (CA INDEX NAME)



RN 1044957-20-1 HCAPLUS
CN Benzenesulfonamide, 4-[5-[1-(4-fluorophenyl)cyclopropyl]-4-(1-methylethyl)-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



RN 1044957-21-2 HCAPLUS
CN 4H-1,2,4-Triazole, 3-(2,4-dichlorophenyl)-5-[1-(4-fluorophenyl)cyclopropyl]-4-(1-methylethyl)- (CA INDEX NAME)



RN 1044957-22-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1044957-23-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1044957-24-5 HCAPLUS
CN 4H-1,2,4-Triazole, 3-(3-chlorophenyl)-5-[1-(4-fluorophenyl)cyclopropyl]-4-(1-methylethyl)- (CA INDEX NAME)



RN 1044957-25-6 HCAPLUS
CN 4H-1,2,4-Triazole, 3-(3,5-dichlorophenyl)-5-[1-(4-fluorophenyl)cyclopropyl]-4-(1-methylethyl)- (CA INDEX NAME)



RN 1044957-46-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1044957-47-2 HCAPLUS
CN Benzenamine, 4-[5-[1-(4-fluorophenyl)cyclopropyl]-4-(1-methylethyl)-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



RN 1044957-48-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1044957-49-4 HCAPLUS
CN Acetamide, N-[2-[3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]phenoxy]ethyl]- (CA INDEX NAME)



RN 1044957-50-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1044957-51-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1044957-55-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



● HCl

RN 1044957-56-3 HCAPLUS
CN 4H-1,2,4-Triazole, 3-(2,3-dichlorophenyl)-5-[1-(4-fluorophenyl)cyclopropyl]-4-methyl- (CA INDEX NAME)



RN 1044957-65-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1044957-67-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1044957-68-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1044957-69-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1044957-70-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1044957-71-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1044957-72-3 HCAPLUS
CN Benzenamine, 3-chloro-4-[5-[1-(4-fluorophenyl)cyclopropyl]-4-methyl-4H-1,2,4-triazol-3-yl]-N-methyl-N-(1-methylethyl)- (CA INDEX NAME)



RN 1044957-73-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1044957-74-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1044957-75-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1044957-76-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1044957-77-8 HCAPLUS
CN Benzenemethanamine, 3-chloro-4-[5-[1-(4-fluorophenyl)cyclopropyl]-4-methyl-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



RN 1044957-78-9 HCAPLUS
CN Benzamide, 3-chloro-4-[5-(1-phenylcyclopropyl)-4-(2,2,2-trifluoroethyl)-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



RN 1044957-79-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1044957-80-3 HCAPLUS
CN 4H-1,2,4-Triazole, 3-(4-fluorophenyl)-5-[1-(4-fluorophenyl)cyclopropyl]-4-(1-methylethyl)- (CA INDEX NAME)



IT 851765-22-5P 851765-23-6P 851765-24-7P
851765-25-8P 851765-26-9P 851765-27-0P
851765-28-1P 851765-29-2P 851765-30-5P
851765-31-6P 851765-32-7P 851765-33-8P
851765-34-9P 851765-35-0P 851765-36-1P
851765-37-2P 851765-38-3P 851765-39-4P
851765-40-7P 851765-41-8P 851765-42-9P
851765-43-0P 851765-44-1P 851765-45-2P
851765-46-3P 851765-47-4P 851765-49-6P
851765-50-9P 851765-51-0P 851765-52-1P
851765-54-3P 851765-55-4P 851765-57-6P
851765-59-8P 851765-61-2P 851765-62-3P

851765-64-5P 851765-65-6P 851765-67-8P
851765-68-9P 851765-70-3P 851765-72-5P
851765-74-7P 851765-76-9P 851765-78-1P
851765-80-5P 851765-81-6P 851765-82-7P
851765-83-8P 851765-84-9P 851765-85-0P
851765-86-1P 851765-87-2P 851765-88-3P
851765-89-4P 851765-90-7P 851765-91-8P
851765-92-9P 851765-93-0P 851765-94-1P
851765-95-2P 851765-96-3P 851765-97-4P
851765-98-5P 851765-99-6P 851766-00-2P
851766-01-3P 851766-02-4P 851766-03-5P
851766-04-6P 851766-05-7P 851766-06-8P
851766-07-9P 851766-08-0P 851766-09-1P
851766-10-4P 851766-11-5P 851766-16-0P
851766-17-1P 851766-18-2P 851766-22-8P
851766-23-9P 851766-24-0P 851766-25-1P
851766-26-2P 851766-29-5P 851766-30-8P
851766-31-9P 851766-32-0P 851766-33-1P
851766-34-2P 851766-35-3P 851766-36-4P
851766-38-6P 851766-40-0P 851766-41-1P
851766-42-2P 851766-43-3P 851766-44-4P
851766-45-5P 851766-46-6P 851766-47-7P
851766-48-8P 851766-49-9P 851766-50-2P
851766-52-4P 851766-53-5P 851766-54-6P
851766-55-7P 851766-56-8P 851766-57-9P
851766-58-0P 851766-59-1P 851766-60-4P
851766-61-5P 851766-62-6P 851766-63-7P
851766-64-8P 851766-65-9P 851766-66-0P
851767-63-0P 851767-64-1P 851767-66-3P
851767-67-4P 851767-68-5P 851768-01-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of triazole compds. as 11β-hydroxysteroid dehydrogenase 1 inhibitors for treatment of diabetes, obesity or metabolic syndrome)

RN 851765-22-5 HCAPLUS
CN 4H-1,2,4-Triazole, 3-(2,4-dichlorophenyl)-4-methyl-5-(1-phenylcyclopropyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 851765-23-6 HCAPLUS
CN 4H-1,2,4-Triazole, 3-(2,4-dichlorophenyl)-5-[1-(4-fluorophenyl)cyclopropyl]-4-methyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 851765-24-7 HCAPLUS
CN 4H-1,2,4-Triazole, 3-(2-chloro-4-nitrophenyl)-4-methyl-5-(1-phenylcyclopropyl)- (CA INDEX NAME)



RN 851765-25-8 HCAPLUS
CN Acetamide, N-[3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 851765-26-9 HCAPLUS
CN Methanesulfonamide, N-[3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]phenyl]- (CA INDEX NAME)



RN 851765-27-0 HCAPLUS
CN Acetamide, N-[3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]phenyl]-2-hydroxy- (CA INDEX NAME)



RN 851765-28-1 HCAPLUS
CN Acetamide, N-[3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]phenyl]-2-methoxy- (CA INDEX NAME)



RN 851765-29-2 HCAPLUS
CN Acetamide, N-[3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]phenyl]-2-(dimethylamino)-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 851765-30-5 HCAPLUS
CN Benzenamine, 3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



RN 851765-31-6 HCAPLUS
CN 2-Pyrrolidinone, 1-[3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 851765-32-7 HCAPLUS
CN Butanamide, N-[3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]phenyl]- (CA INDEX NAME)



RN 851765-33-8 HCAPLUS
CN Propanamide, N-[3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]phenyl]-2-methyl- (CA INDEX NAME)



RN 851765-34-9 HCAPLUS
CN 4-Morpholinecarboxamide, N-[3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]phenyl]- (CA INDEX NAME)



RN 851765-35-0 HCAPLUS
CN 4-Morpholineacetamide, N-[3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]phenyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 851765-36-1 HCAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]phenyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 851765-37-2 HCAPLUS
CN Urea, N'-[3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]phenyl]-N,N-dimethyl- (CA INDEX NAME)



RN 851765-38-3 HCAPLUS
CN Sulfamide, N-[3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 851765-39-4 HCAPLUS
CN Urea, N-[3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]phenyl]- (CA INDEX NAME)



RN 851765-40-7 HCAPLUS
CN 2-Oxazolidinone, 3-[3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]phenyl]- (CA INDEX NAME)



RN 851765-41-8 HCAPLUS
CN Ethanol, 2-[[3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]phenyl]amino]- (CA INDEX NAME)



RN 851765-42-9 HCAPLUS
CN Carbamic acid, [3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 851765-43-0 HCAPLUS
CN 2-Imidazolidinone, 1-[3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]phenyl]- (CA INDEX NAME)



RN 851765-44-1 HCAPLUS
CN 1-Piperidinecarboxamide, N-[3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]phenyl]-4-methoxy- (CA INDEX NAME)



RN 851765-45-2 HCAPLUS
CN 1-Piperidinecarboxamide, N-[3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]phenyl]-3-hydroxy- (CA INDEX NAME)



RN 851765-46-3 HCAPLUS
CN 1-Piperidinecarboxamide, N-[3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]phenyl]-4-hydroxy- (CA INDEX NAME)



RN 851765-47-4 HCAPLUS
CN 1-Piperidineacetamide, N-[3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]phenyl]-4-hydroxy- (CA INDEX NAME)



RN 851765-49-6 HCAPLUS
CN 1-Piperidineacetamide, N-[3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]phenyl]-3-hydroxy- (CA INDEX NAME)



RN 851765-50-9 HCAPLUS
CN 1-Piperidineacetamide, N-[3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]phenyl]-4-methoxy- (CA INDEX NAME)



RN 851765-51-0 HCAPLUS
CN Morpholine, 4-[4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]phenyl]- (CA INDEX NAME)



RN 851765-52-1 HCAPLUS
CN Acetamide, N-[3-chloro-4-[5-[1-(4-fluorophenyl)cyclopropyl]-4-methyl-4H-1,2,4-triazol-3-yl]phenyl]- (CA INDEX NAME)



RN 851765-54-3 HCAPLUS
CN Piperazine, 1-[3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]phenyl]-, hydrochloride (1:3) (CA INDEX NAME)



●3 HCl

RN 851765-55-4 HCAPLUS
CN Ethanone, 1-[4-[3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]phenyl]-1-piperazinyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 851765-57-6 HCAPLUS
CN Piperazine, 1-[3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-

triazol-3-yl]phenyl]-4-(methylsulfonyl)- (CA INDEX NAME)



RN 851765-59-8 HCAPLUS
CN 1-Propanone, 1-[4-[3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]phenyl]-1-piperazinyl]-2-methyl-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 851765-61-2 HCAPLUS
CN 1-Piperazinecarboxamide, 4-[3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]phenyl]-N,N-dimethyl-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 851765-62-3 HCAPLUS
CN Piperidine, 1-[3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]phenyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 851765-64-5 HCAPLUS
CN 4-Piperidinol, 1-[3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]phenyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 851765-65-6 HCAPLUS
CN Morpholine, 4-[3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]phenyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 851765-67-8 HCAPLUS
CN Piperidine, 1-[3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]phenyl]-4-methyl-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 851765-68-9 HCAPLUS
CN 4H-1,2,4-Triazole, 3-[2-chloro-4-(1-pyrrolidinyl)phenyl]-4-methyl-5-(1-phenylcyclopropyl)-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 851765-70-3 HCAPLUS
CN 4-Piperidinecarboxylic acid, 1-[3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]phenyl]-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 851765-72-5 HCAPLUS
CN 4-Piperidinecarboxylic acid, 1-[3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]phenyl]- (CA INDEX NAME)



RN 851765-74-7 HCAPLUS
CN 4-Piperidinecarboxamide, 1-[3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]phenyl]-N-methyl- (CA INDEX NAME)



RN 851765-76-9 HCAPLUS
CN 1,4-Dioxa-8-azaspiro[4.5]decane, 8-[3-chloro-4-[4-methyl-5-(1-

phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]phenyl]- (CA INDEX NAME)



RN 851765-78-1 HCAPLUS
CN 4-Piperidinecarboxylic acid, 1-[3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]phenyl]-, 2-methoxyethyl ester, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 851765-80-5 HCAPLUS
CN Carbamic acid, [1-[3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]phenyl]-4-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 851765-81-6 HCAPLUS
CN 4-Piperidinamine, 1-[3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]phenyl]-, hydrochloride (1:3) (CA INDEX NAME)



●3 HCl

RN 851765-82-7 HCAPLUS
CN Acetamide, N-[1-[3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]phenyl]-4-piperidinyl]- (CA INDEX NAME)



RN 851765-83-8 HCAPLUS
CN 3-Piperidinol, 1-[3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]phenyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 851765-84-9 HCAPLUS
CN 4H-1,2,4-Triazole, 3-[2-chloro-4-[(4-methoxyphenyl)methoxy]phenyl]-4-

methyl-5-(1-phenylcyclopropyl)- (CA INDEX NAME)



RN 851765-85-0 HCAPLUS
CN Phenol, 3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 851765-86-1 HCAPLUS
CN Acetamide, 2-[3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]phenoxy]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 851765-87-2 HCAPLUS
CN Benzoic acid, 3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 851765-88-3 HCAPLUS
CN 4H-1,2,4-Triazole, 3-[2-chloro-4-(methylsulfonyl)phenyl]-4-methyl-5-(1-phenylcyclopropyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 851765-89-4 HCAPLUS
CN Benzoic acid, 3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 851765-90-7 HCAPLUS
CN Benzamide, 3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



RN 851765-91-8 HCAPLUS
CN Methanone, [3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]phenyl]-4-morpholinyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 851765-92-9 HCAPLUS
CN Benzamide, 3-chloro-N-methyl-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 851765-93-0 HCAPLUS
CN 4H-1,2,4-Triazole, 3-(2-chloro-4-methoxyphenyl)-4-methyl-5-(1-phenylcyclopropyl)- (CA INDEX NAME)



RN 851765-94-1 HCAPLUS
CN Benzamide, 3-chloro-N,N-dimethyl-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 851765-95-2 HCAPLUS
CN Benzamide, 3-chloro-N-(2-hydroxyethyl)-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



RN 851765-96-3 HCAPLUS
CN Benzamide, 3-chloro-N-(1-methylethyl)-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



RN 851765-97-4 HCAPLUS
CN Methanone, [3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]phenyl]-1-piperidinyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 851765-98-5 HCAPLUS
CN Methanone, [3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]phenyl](4-hydroxy-1-piperidinyl)- (CA INDEX NAME)



RN 851765-99-6 HCAPLUS
CN Benzamide, N-(2-amino-2-oxoethyl)-3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



RN 851766-00-2 HCAPLUS
CN Benzamide, 3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]-N-(2,2,2-trifluoroethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 851766-01-3 HCAPLUS
CN Benzamide, N-[2-(acetylamino)ethyl]-3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 851766-02-4 HCAPLUS
CN Benzamide, 3-chloro-N-(2-methoxyethyl)-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 851766-03-5 HCAPLUS
CN Ethanone, 1-[4-[3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]benzoyl]-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 851766-04-6 HCAPLUS
CN Benzamide, 3-chloro-N-[2-(dimethylamino)ethyl]-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



RN 851766-05-7 HCAPLUS
CN Benzamide, 3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)



RN 851766-06-8 HCAPLUS
CN Benzenamine, 3-chloro-N,N-dimethyl-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 851766-07-9 HCAPLUS
CN 4H-1,2,4-Triazole, 3-(4-chloro-2-methoxyphenyl)-4-methyl-5-(1-phenylcyclopropyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 851766-08-0 HCAPLUS
CN 4H-1,2,4-Triazole, 3-(2-chloro-4-fluorophenyl)-4-methyl-5-(1-phenylcyclopropyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 851766-09-1 HCAPLUS
CN 4H-1,2,4-Triazole, 3-(4-chloro-2-nitrophenyl)-4-methyl-5-(1-phenylcyclopropyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 851766-10-4 HCAPLUS
CN Benzenamine, 5-chloro-2-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 851766-11-5 HCAPLUS
CN 4H-1,2,4-Triazole, 3-(4-chloro-2-fluorophenyl)-4-methyl-5-(1-phenylcyclopropyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 851766-16-0 HCAPLUS
CN 4H-1,2,4-Triazole, 3-(4-bromo-2-chlorophenyl)-4-methyl-5-(1-phenylcyclopropyl)- (CA INDEX NAME)



RN 851766-17-1 HCAPLUS
CN 4H-1,2,4-Triazole, 3-(2-chlorophenyl)-4-methyl-5-(1-phenylcyclopropyl)- (CA INDEX NAME)



RN 851766-18-2 HCAPLUS
CN Benzenemethanol, 3-chloro-α-methyl-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]-α-(trifluoromethyl)- (CA INDEX NAME)



RN 851766-22-8 HCAPLUS
CN 4H-1,2,4-Triazole, 3-(4-chlorophenyl)-5-[1-(4-fluorophenyl)cyclopropyl]-4-(1-methylethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 851766-23-9 HCAPLUS
CN 4H-1,2,4-Triazole, 3-(2,4-dichlorophenyl)-5-[1-(4-fluorophenyl)cyclopropyl]-4-methyl- (CA INDEX NAME)



RN 851766-24-0 HCAPLUS
CN 4-Piperidinemethanol, 1-[3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]phenyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 851766-25-1 HCAPLUS
CN 4-Piperidinecarboxamide, 1-[3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]phenyl]- (CA INDEX NAME)



RN 851766-26-2 HCAPLUS
CN 4-Piperidinecarboxamide, 1-[3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]phenyl]-N-(2-methoxyethyl)- (CA INDEX NAME)



RN 851766-29-5 HCAPLUS
CN Methanone, [1-[3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-

triazol-3-yl]phenyl]-4-piperidinyl]-1-piperidinyl- (CA INDEX NAME)



RN 851766-30-8 HCAPLUS
CN Methanone, [1-[3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]phenyl]-4-piperidinyl]-4-morpholinyl- (CA INDEX NAME)



RN 851766-31-9 HCAPLUS
CN 4-Piperidinecarboxamide, 1-[3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]phenyl]-N,N-dimethyl- (CA INDEX NAME)



RN 851766-32-0 HCAPLUS
CN 4-Piperidinecarboxamide, 1-[3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]phenyl]-N-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 851766-33-1 HCAPLUS
CN Urea, N-[1-[3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]phenyl]-4-piperidinyl]-N'-methoxy- (CA INDEX NAME)



RN 851766-34-2 HCAPLUS
CN 2-Oxazolidinone, 3-[3-chloro-4-[5-[1-(4-fluorophenyl)cyclopropyl]-4-methyl-4H-1,2,4-triazol-3-yl]phenyl]- (CA INDEX NAME)



RN 851766-35-3 HCAPLUS
CN Ethanol, 2-[3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]phenoxy]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 851766-36-4 HCAPLUS
CN Ethanol, 2-[[3-chloro-4-[5-[1-(4-fluorophenyl)cyclopropyl]-4-methyl-4H-1,2,4-triazol-3-yl]phenyl]amino]- (CA INDEX NAME)



RN 851766-38-6 HCAPLUS
CN 4H-1,2,4-Triazole, 3-(2,5-dichlorophenyl)-5-[1-(4-fluorophenyl)cyclopropyl]-4-methyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 851766-40-0 HCAPLUS
CN Benzoic acid, 3-methoxy-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



RN 851766-41-1 HCAPLUS
CN Benzamide, 3-methoxy-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



RN 851766-42-2 HCAPLUS
CN Benzoic acid, 3-chloro-4-[5-[1-(4-fluorophenyl)cyclopropyl]-4-methyl-4H-1,2,4-triazol-3-yl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 851766-43-3 HCAPLUS
CN Benzamide, 3-chloro-4-[5-[1-(4-fluorophenyl)cyclopropyl]-4-methyl-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



RN 851766-44-4 HCAPLUS
CN Benzamide, 3-chloro-4-[5-[1-(4-fluorophenyl)cyclopropyl]-4-methyl-4H-1,2,4-triazol-3-yl]-N-methyl- (CA INDEX NAME)



RN 851766-45-5 HCAPLUS
CN 4H-1,2,4-Triazole, 3-[2-chloro-4-(2,2,2-trifluoroethoxy)phenyl]-4-methyl-5-(1-phenylcyclopropyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 851766-46-6 HCAPLUS
CN Ethanamine, 2-[3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]phenoxy]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 851766-47-7 HCAPLUS
CN 3-Pyrrolidinol, 1-[3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]phenyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 851766-48-8 HCAPLUS
CN Benzamide, 4-[4-(1-methylethyl)-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



RN 851766-49-9 HCAPLUS
CN 4H-1,2,4-Triazole, 3-(2-chlorophenyl)-5-[1-(4-fluorophenyl)cyclopropyl]-4-methyl- (CA INDEX NAME)



RN 851766-50-2 HCAPLUS
CN Urea, N'-[3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]phenyl]-N-hydroxy-N-methyl- (CA INDEX NAME)



RN 851766-52-4 HCAPLUS
CN Benzamide, 4-[5-[1-(4-fluorophenyl)cyclopropyl]-4-(1-methylethyl)-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



RN 851766-53-5 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[5-[1-(4-fluorophenyl)cyclopropyl]-4-(1-methylethyl)-4H-1,2,4-triazol-3-yl]phenyl]- (CA INDEX NAME)



RN 851766-54-6 HCAPLUS
CN Carbamic acid, [4-chloro-3-[5-[1-(4-fluorophenyl)cyclopropyl]-4-methyl-4H-1,2,4-triazol-3-yl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 851766-55-7 HCAPLUS
CN 2-Oxazolidinone, 3-[4-chloro-3-[5-[1-(4-fluorophenyl)cyclopropyl]-4-methyl-4H-1,2,4-triazol-3-yl]phenyl]- (CA INDEX NAME)



RN 851766-56-8 HCAPLUS
CN Urea, N-[3-chloro-4-[5-[1-(4-fluorophenyl)cyclopropyl]-4-methyl-4H-1,2,4-triazol-3-yl]phenyl]-N'-methoxy- (CA INDEX NAME)



RN 851766-57-9 HCAPLUS
CN Urea, N-[4-[5-[1-(4-fluorophenyl)cyclopropyl]-4-(1-methylethyl)-4H-1,2,4-triazol-3-yl]phenyl]-N'-methoxy- (CA INDEX NAME)



RN 851766-58-0 HCAPLUS
CN 2-Oxazolidinone, 3-[3-[5-[1-(4-fluorophenyl)cyclopropyl]-4-(1-methylethyl)-4H-1,2,4-triazol-3-yl]phenyl]- (CA INDEX NAME)



RN 851766-59-1 HCAPLUS
CN Urea, N-[3-[5-[1-(4-fluorophenyl)cyclopropyl]-4-(1-methylethyl)-4H-1,2,4-triazol-3-yl]phenyl]-N'-methoxy- (CA INDEX NAME)



RN 851766-60-4 HCAPLUS
CN Benzamide, 4-chloro-3-[5-[1-(4-fluorophenyl)cyclopropyl]-4-methyl-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



RN 851766-61-5 HCAPLUS
CN Benzamide, 4-chloro-3-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



RN 851766-62-6 HCAPLUS
CN Benzamide, 3-chloro-4-[4-ethyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



RN 851766-63-7 HCAPLUS
CN Benzamide, 3-chloro-4-[4-ethyl-5-[1-(4-fluorophenyl)cyclopropyl]-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



RN 851766-64-8 HCAPLUS
CN Benzamide, 3-[4-(1-methylethyl)-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



RN 851766-65-9 HCAPLUS
CN Benzamide, 3-[5-[1-(4-fluorophenyl)cyclopropyl]-4-(1-methylethyl)-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



RN 851766-66-0 HCAPLUS
CN Benzenemethanol, 4-chloro-α-methyl-3-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]-α-(trifluoromethyl)- (CA INDEX NAME)



RN 851767-63-0 HCAPLUS
CN Methanone, [3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]phenyl]-4-morpholinyl- (CA INDEX NAME)



RN 851767-64-1 HCAPLUS
CN Benzamide, 3-chloro-N-methyl-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



RN 851767-66-3 HCAPLUS
CN Benzamide, 3-chloro-N,N-dimethyl-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



RN 851767-67-4 HCAPLUS
CN Methanone, [3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]phenyl]-1-piperidinyl- (CA INDEX NAME)



RN 851767-68-5 HCAPLUS
CN Ethanone, 1-[4-[3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]benzoyl]-1-piperazinyl]- (CA INDEX NAME)



RN 851768-01-9 HCAPLUS
CN Morpholine, 4-[3-chloro-4-[5-[1-(4-fluorophenyl)cyclopropyl]-4-methyl-4H-1,2,4-triazol-3-yl]phenyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:991491 HCAPLUS
DOCUMENT NUMBER: 140:27832
TITLE: Preparation of triazolyl 11β-hydroxysteroid dehydrogenase-1 inhibitors for the treatment of diabetes, obesity and dyslipidemia
INVENTOR(S): Olson, Steven H.; Balkovec, James M.; Zhu, Yuping
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 144 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2003104208	A1	20031218	WO 2003-US17890		20030606
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2488592	A1	20031218	CA 2003-2488592		20030606
AU 2003251410	A1	20031222	AU 2003-251410		20030606
EP 1532122	A1	20050525	EP 2003-757385		20030606
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
CN 1659151	A	20050824	CN 2003-813392		20030606
CN 1312137	C	20070425			
CN 1990474	A	20070704	CN 2007-10003770		20030606
US 20040048912	A1	20040311	US 2003-457682		20030609
US 6730690	B2	20040504			
US 20040106664	A1	20040603	US 2003-697547		20031030
US 7179802	B2	20070220			
ZA 2004008772	A	20051118	ZA 2004-8772		20041029
PRIORITY APPLN. INFO.:			US 2002-387385P	P	20020610
			CN 2003-813392	A3	20030606
			WO 2003-US17890	W	20030606
			US 2003-457682	A3	20030609

OTHER SOURCE(S): MARPAT 140:27832

GI



I



II

AB Title compds. I [A = halo, alkyl, Ph, etc.; B = H, halo, alkyl, S-alkyl, etc. or A, B = taken together are (un)substituted alkylene; R1 = H, OH, halo, alkyl, alkoxy, aryl, etc.; R2 = alkyl, alkoxy, Ph, etc.; R3 = alkyl, alkenyl, thioalkoxy, aryl, heterocyclyl, etc. or R2-3 = taken together fused 5-6-membered alkyl/aryl ring] are prepared For instance, 2,2-diphenylbutanoic acid is converted to the corresponding hydrazide (DMF, Et3N, TFFH, H2NNH2, 0°, 30 min). 8-Methoxy-2,3,4,5,6,7-hexahydroazocine is then reacted with the intermediate (DMF, 120°, overnight) to give II. Example compds. exhibit IC50 < 500 nM for 11β-hydroxysteroid dehydrogenase-1 (11β-HSD1). I are useful for the treatment of diabetes, such as noninsulin-dependent diabetes (NIDDM), hyperglycemia, obesity, insulin resistance, dylsipidemia, hyperlipidemia, hypertension, Syndrome X and other symptoms associated with NIDDM.

IT 633317-12-1P 633317-13-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of triazolyl 11β-hydroxysteroid dehydrogenase-1 inhibitors for treatment of diabetes, obesity and dyslipidemia)

RN 633317-12-1 HCAPLUS
CN 4H-1,2,4-Triazole, 3-[1-(4-chlorophenyl)cyclopropyl]-4-methyl-5-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



RN 633317-13-2 HCAPLUS
CN 4H-1,2,4-Triazole, 3-[1-(4-fluorophenyl)cyclopropyl]-4-methyl-5-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:991490 HCAPLUS
DOCUMENT NUMBER: 140:27831
TITLE: Preparation of triazolyl 11β-hydroxysteroid dehydrogenase-1 inhibitors for the treatment of diabetes, obesity and dyslipidemia
INVENTOR(S): Olson, Steven H.; Balkovec, James M.; Zhu, Yuping
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 91 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003104207	A2	20031218	WO 2003-US17898	20030606

WO 2003104207		A3	20040325				
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,						
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,						
	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS,						
	LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH,						
	PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,						
	UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW						
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,						
	KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,						
	FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,						
	BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG						
AU 2003243420		A1	20031222	AU 2003-243420			20030606
BR 2003011137		A	20050222	BR 2003-11137			20030606
CN 1659151		A	20050824	CN 2003-813392			20030606
CN 1312137		C	20070425				
JP 2005532357		T	20051027	JP 2004-511277			20030606
NZ 536188		A	20061130	NZ 2003-536188			20030606
CN 1990474		A	20070704	CN 2007-10003770			20030606
RU 2319703		C2	20080320	RU 2004-139063			20030606
US 20040048912		A1	20040311	US 2003-457682			20030609
US 6730690		B2	20040504				
US 20040106664		A1	20040603	US 2003-697547			20031030
US 7179802		B2	20070220				
ZA 2004008772		A	20051118	ZA 2004-8772			20041029
MX 2004012381		A	20050419	MX 2004-12381			20041209
IN 2004CN02787		A	20060210	IN 2004-CN2787			20041209
NO 2005000102		A	20050210	NO 2005-102			20050107
HK 1081946		A1	20071207	HK 2006-102016			20060216
PRIORITY APPLN. INFO.:				US 2002-387385P		P	20020610
				CN 2003-813392		A3	20030606
				WO 2003-US17898		W	20030606
				US 2003-457682		A3	20030609

OTHER SOURCE(S): MARPAT 140:27831

GI



I



II

AB Title compds. I [A = halo, alkyl, Ph, etc.; B = H, halo, alkyl, S-alkyl, etc. or A, B = taken together are (un)substituted alkylene; R1 = H, OH, halo, alkyl, alkoxy, aryl, etc.; R2 = alkyl, alkoxy, Ph, etc.; R3 = alkyl, alkenyl, thioalkoxy, aryl, heterocyclyl, etc. or R2-3 = taken together fused 5-6-membered alkyl/aryl ring] are prepared For instance, 2,2-diphenylbutanoic acid is converted to the corresponding hydrazide (DMF, Et3N, TFFH, H2NNH2, 0°, 30 min). 8-Methoxy-2,3,4,5,6,7-hexahydroazocine is then reacted with the intermediate (DMF, 120°, overnight) to give II. Example compds. exhibit IC50 < 500 nM for 11β-hydroxysteroid dehydrogenase-1 (11β-HSD1). I are useful for the treatment of diabetes, such as noninsulin-dependent diabetes (NIDDM), hyperglycemia, obesity, insulin

resistance, dylsipidemia, hyperlipidemia, hypertension, Syndrome X and other symptoms associated with NIDDM.

IT 633317-12-1P 633317-13-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of triazolyl 11β-hydroxysteroid dehydrogenase-1 inhibitors for treatment of diabetes, obesity and dyslipidemia)

RN 633317-12-1 HCAPLUS
CN 4H-1,2,4-Triazole, 3-[1-(4-chlorophenyl)cyclopropyl]-4-methyl-5-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



RN 633317-13-2 HCAPLUS
CN 4H-1,2,4-Triazole, 3-[1-(4-fluorophenyl)cyclopropyl]-4-methyl-5-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l23 ibib abs hitstr tot

L23 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:423718 HCAPLUS
DOCUMENT NUMBER: 142:482046
TITLE: Preparation of triazole compounds as 11β-hydroxysteroid dehydrogenase 1 inhibitors
INVENTOR(S): Cardozo, Mario G.; Powers, Jay P.; Goto, Hiroyuki; Harada, Kazuhito; Imamura, Katsuaki; Kakutani, Makoto; Matsuda, Isamu; Ohe, Yasuhiro; Yata, Shinji
PATENT ASSIGNEE(S): Amgen SF LLC, USA; Japan Tobacco, Inc.
SOURCE: PCT Int. Appl., 107 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005044192	A2	20050519	WO 2004-US35805	20041027
WO 2005044192	A3	20050909		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004286836	A1	20050519	AU 2004-286836	20041027
CA 2543602	A1	20050519	CA 2004-2543602	20041027
EP 1680114	A2	20060719	EP 2004-796647	20041027
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
JP 2007509959	T	20070419	JP 2006-538245	20041027
MX 2006004674	A	20061120	MX 2006-4674	20060426
US 20080249084	A1	20081009	US 2006-587846	20060905

PRIORITY APPLN. INFO.: US 2003-515537P P 20031028
WO 2004-US35805 W 20041027

OTHER SOURCE(S): CASREACT 142:482046; MARPAT 142:482046
GI



I



AB The present invention provides triazole compds. of the following formula (I)or prodrugs thereof or pharmaceutically acceptable salts thereof [R1 = (un)substituted alkyl or cycloalkyl; Y = each (un)substituted cycloalkyl or heterocycloalkyl; Ar1 = aryl, heteroaryl; R2, R3 = H, halo, haloalkyl,

alkyl group, (CH2)nOH, -N(R9)(R10), cyano, NO2, alkoxy, cycloalkyl, alkenyl, COR11, each (un)substituted aryl or heteroaryl group [wherein R9, R10 = H, alkyl,alkylcarbonyl; R11 = OH, alkoxy, alkyl, (un)substituted NH2; n = 0-3]; Z = [CH(R14)]p, [CH(R14)]p-N(R16)[CH(R15)]q, each (un)substituted cycloalkylidene or heterocycloalkylidene [wherein p, q = 0-3; R14, R15 = group listed in R9 and R10]; Ar2 = aryl, heteroaryl, Q, Q1, Q2 [wherein X1 = (CH2)t; t = 0-2; V1 = :CH, :N; W1 = (un)substituted CH2, O, S, SO2, SO, CO, (un)substituted NH]; R4, R5 = H, halo, OH, NO2, cyano, alkyl, alkoxy, COR27, SO2R27, each (un)substituted CONH2 or NH2; R27 = OH, alkoxy, alkyl, NH2, alkylamino, dialkylamino]. These triazole compds. are 11β-hydroxysteroid dehydrogenase 1-(11β-HSD1 or HSD1) and useful as therapeutic drugs for the treatment of diabetes, obesity or metabolic syndrome. Thus, Me N-methyl-4-phenylpiperidine-1-imidethiocarboxylate hydroiodide (452 mg) and 1-phenylcyclopropane carbohydrazide (176 mg) were suspended in 1,4-dioxane (2 mL) and water (0.4 mL) and sodium acetate (98 mg) were added and the mixture was heated under reflux overnight to give, after workup and silica gel chromatog., 117 mg 1-[4-methyl-5-(1-phenylcyclopropyl)-4H-[1,2,4]triazol-3-yl]-4-phenylpiperidine hydrochloride (II). II showed IC50 of <10 nM against human HSD1.

IT 851765-35-0P 851765-47-4P 851765-49-6P
851765-50-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of triazole compds. as 11β-hydroxysteroid dehydrogenase 1 inhibitors for treatment of diabetes, obesity or metabolic syndrome)

RN 851765-35-0 HCAPLUS

CN 4-Morpholineacetamide, N-[3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]phenyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 851765-47-4 HCAPLUS

CN 1-Piperidineacetamide, N-[3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]phenyl]-4-hydroxy- (CA INDEX NAME)



RN 851765-49-6 HCAPLUS
CN 1-Piperidineacetamide, N-[3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]phenyl]-3-hydroxy- (CA INDEX NAME)



RN 851765-50-9 HCAPLUS
CN 1-Piperidineacetamide, N-[3-chloro-4-[4-methyl-5-(1-phenylcyclopropyl)-4H-1,2,4-triazol-3-yl]phenyl]-4-methoxy- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	53.79	1364.77

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION

CA SUBSCRIBER PRICE -4.92 -4.92

STN INTERNATIONAL LOGOFF AT 11:02:13 ON 21 APR 2009